Table 3:
The involvement of soluble plasma proteins in different biological processes categorized according to the public access bioinformatics databases Uniprot, human protein atlas, gene ontology, and DisGeNET. Proteins with statistically significant and minimum 20% difference during tofacitinib treatment are shown. Eighteen proteins that decreased during tofacitinib treatment are shown on the left, and three proteins that increased on the right.
| Biological process | IL-6 | IL-7 | IL-10 | IL-12B | TNFSF14 | TNFRSF9 | CCL7 | CCL8 | CCL13 | CCL19 | CXCL1 | CXCL11 | MMP-1 | AXIN1 | EN-RAGE | OSM | SIRT2 | STAMBP | CX3CL1 | MMP-10 | Flt3L | Count |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cellular response to cytokine stimulus | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 15 | ||||||
| Inflammatory response | X | X | X | X | X | X | X | X | X | X | X | X | X | X | 14 | |||||||
| Apoptotic process | X | X | X | X | X | X | X | X | X | X | X | X | 12 | |||||||||
| Chemotaxis | X | X | X | X | X | X | X | X | X | X | X | 11 | ||||||||||
| MAPK cascade | X | X | X | X | X | X | X | X | X | 9 | ||||||||||||
| Secretion | X | X | X | X | X | X | X | X | X | 9 | ||||||||||||
| Cell adhesion | X | X | X | X | X | X | X | X | 8 | |||||||||||||
| Cell activation in immune response | X | X | X | X | X | X | 6 | |||||||||||||||
| Regulation of immune response | X | X | X | X | 4 | |||||||||||||||||
| Extracellular matrix organization | X | X | 2 | |||||||||||||||||||
| Response to hypoxia | X | 1 |
Mitogen-activated protein kinase (MAPK); interleukin (IL); tumor necrosis factor superfamily member 14 (TNFSF14); tumor necrosis factor receptor superfamily member 9 (TNFRSF9); C–C motif chemokine (CCL); C-X-C motif chemokine ligand (CXCL); C-X3-C motif chemokine ligand (CX3CL); matrix metalloproteinase (MMP);S100 calcium-binding protein A12 (EN-RAGE); Oncostatin M (OSM); NAD-dependent deacetylase sirtuin 2 (SIRT2); STAM-binding protein (STAMBP); FMS-like tyrosine kinase 3 ligand (Flt3L).